Clinical Trials Directory

Trials / Completed

CompletedNCT06344767

Positive ER Expression Assessed by 18F-FES PET/CT in the MBC with ER-negative Primary Tumor

Positive Estrogen Receptor (ER) Expression Assessed by 18F-fluoroestradiol Positron Emission Tomography/Computed Tomography (18F-FES PET/CT) in the Metastatic Breast Cancer (MBC) with ER- Negative Primary Tumor

Status
Completed
Phase
Study type
Observational
Enrollment
19 (actual)
Sponsor
Fudan University · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

To investigate the treatment pattern and efficacy of patients with negative primary ER lesion but positive ER expression in MBC using a novel convenient way of 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT).

Conditions

Timeline

Start date
2023-09-01
Primary completion
2024-05-05
Completion
2024-05-05
First posted
2024-04-03
Last updated
2024-10-08

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06344767. Inclusion in this directory is not an endorsement.

Positive ER Expression Assessed by 18F-FES PET/CT in the MBC with ER-negative Primary Tumor (NCT06344767) · Clinical Trials Directory